Current Treatment Options in Cardiovascular Medicine is a leading journal dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by SpringerNature, this journal seeks to bridge the gap between clinical practice and research by providing comprehensive reviews, insightful analyses, and updates on the latest treatment modalities available for cardiovascular diseases. With an ISSN of 1092-8464 and an E-ISSN of 1534-3189, it displays a commitment to disseminating critical information to healthcare professionals and researchers globally. Despite its recent categorization in the Q3 quartile, the journal continues to maintain relevance with a Scopus rank of #246 in the field, reflecting its contribution to the ongoing discourse in cardiovascular care. The publication encompasses a broad spectrum of topics, from interventional cardiology to pharmacotherapy, supporting the journal's objective to enhance patient care through evidence-based treatment options. Researchers, professionals, and students will find Current Treatment Options in Cardiovascular Medicine an indispensable resource for staying at the forefront of cardiovascular innovations and applications.

Cardiology Journal, published by VIA MEDICA, stands as a prominent resource in the field of cardiology and cardiovascular medicine, with an ISSN of 1897-5593 and an E-ISSN of 1898-018X. Recognized for its Open Access model established since 1994, this journal facilitates widespread dissemination of critical research findings, allowing practitioners and researchers globally to access valuable insights without barriers. Based in Poland, with an address at UL SWIETOKRZYSKA 73, 80-180 GDANSK, it has achieved a respectable Q2 classification in 2023 for both Cardiology and Miscellaneous Medicine categories, reflecting its influence and quality within the scholarly community. With a Scopus ranking placing it at #117 out of 387 in Cardiology, it lies within the 69th percentile, underpinning its commitment to advancing knowledge in cardiovascular health. The journal’s converged years extending from 2006 to 2024 ensure it captures ongoing developments in a rapidly evolving field. As such, the Cardiology Journal serves as an indispensable platform for researchers, professionals, and students dedicated to exploring the frontiers of cardiac science and improving patient care.

Research Reports in Clinical Cardiology is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of clinical cardiology. Since its inception in 2010, the journal has become an essential resource for researchers, practitioners, and students seeking the latest insights and developments in cardiovascular research. With its commitment to disseminating high-quality research, Research Reports in Clinical Cardiology continually explores crucial topics ranging from innovative therapeutic interventions to the epidemiology of heart diseases, attracting contributions from leading experts in the field. The journal's open-access model ensures that vital research findings are accessible to a global audience, fostering collaboration and the exchange of knowledge. By prioritizing impactful and rigorous studies, this journal plays a significant role in shaping contemporary cardiovascular medicine and providing essential resources for ongoing education in this vital area of healthcare.

KARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.

CURRENT PROBLEMS IN CARDIOLOGY is a leading peer-reviewed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of cardiology through comprehensive analyses of contemporary challenges faced by cardiovascular practitioners. With its ISSN 0146-2806 and E-ISSN 1535-6280, this esteemed journal has been a crucial resource for researchers, clinicians, and students alike since its inception in 1976, and continues to publish groundbreaking studies and reviews up until 2024. As a testament to its scholarly impact, CURRENT PROBLEMS IN CARDIOLOGY boasts a prestigious Q1 ranking in both Cardiology and Cardiovascular Medicine, as well as in the broader category of Medicine (miscellaneous) in the 2023 metrics, positioning it among the top journals in its field. With a Scopus ranking of #127 out of 387 in Cardiology, and a 67th percentile ranking, it remains a vital platform for disseminating high-quality research that addresses critical issues in cardiovascular health. Researchers and practitioners looking to stay at the forefront of cardiac medicine will find this journal an indispensable tool for informed decision-making and practice improvement.

World Journal of Cardiology, published by BAISHIDENG PUBLISHING GROUP INC, stands out as a pivotal resource in the field of cardiology and cardiovascular medicine. With an ISSN of 1949-8462, this journal serves a global audience, promoting knowledge dissemination and collaboration among researchers, healthcare professionals, and students dedicated to advancing cardiovascular health. The journal demonstrates its credibility and impact in the field by achieving a respectable Q2 ranking in the 2023 category of Cardiology and Cardiovascular Medicine. Notably, it is listed in the Scopus database, ranking #189 out of 387 journals, placing it in the 51st percentile, which underscores its relevance and contribution to contemporary cardiovascular research. Although it operates under a subscription model, the journal provides diverse access options, ensuring that critical findings reach a wide audience. Through its comprehensive scope and commitment to publishing high-quality articles, the World Journal of Cardiology plays a vital role in shaping the future of cardiovascular science, making it an invaluable asset for those involved in this essential discipline.

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

Expert Review of Cardiovascular Therapy is a leading academic journal published by TAYLOR & FRANCIS INC, focusing on innovative and impactful research in the field of cardiovascular medicine. With an ISSN of 1477-9072 and an E-ISSN of 1744-8344, this journal serves as an essential resource for researchers, clinicians, and educators, offering a platform for the dissemination of critical advancements in cardiovascular therapy and internal medicine. Since its inception in 2003, the journal has maintained a reputable standing with a Q2 ranking in various categories including Cardiology and Cardiovascular Medicine, reflecting its influence and rigor in the field. The journal, which is based in the United Kingdom, does not currently offer Open Access options, ensuring that its content is accessible primarily to subscribers. With its commitment to high-quality, peer-reviewed articles, Expert Review of Cardiovascular Therapy is dedicated to bridging the gap between experimental research and clinical application, thereby enhancing patient care and therapeutic outcomes in cardiovascular health.

Revista Portuguesa de Cardiologia, published by Elsevier España SLU, stands as a pivotal resource in the realm of Cardiology and Cardiovascular Medicine. With its origins tracing back to 1970, this journal has cultivated a robust academic presence, achieving a 2023 Q3 ranking in its category, and currently holding a position of #220 out of 387 on the Scopus rankings, placing it within the 43rd percentile of its field. This open access journal, available since 2011, aims to disseminate high-quality research and insights relevant to contemporary cardiovascular issues. Its commitment to accessibility and knowledge exchange enhances its importance for clinicians, researchers, and students alike, fostering a more informed community in the fight against cardiovascular diseases. Operating from its base in Barcelona, Spain, the journal welcomes contributions that further the understanding and treatment of heart conditions, contributing significantly to the advancement of cardiovascular health.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.